Prof. Boheng Zhang | Liver cancer | Best Researcher Award

Posted on by Pencis

Prof. Boheng Zhang | Liver cancer | Best Researcher Award

Zhongshan Hospital, Fudan University | China

Author Profile

Scopus

💼Professor Zhang Boheng 🎓🧬

Title:

Party Secretary and Executive Director of the Hepatocellular Carcinoma Department at Xiamen Hospital, affiliated with Zhongshan Hospital, Fudan University.

🎓Education and Training:

  • Doctor of Medicine (1996-1999): Fudan University
  • Master of Medicine (Clinical Epidemiology) (1992-1996): The University of Newcastle, Australia
  • Bachelor of Medicine (1983-1989): Fudan University School of Public Health
  • Advanced Training (2001-2002): Monash Medical School, Australia, and The Alfred Hospital

👨‍⚕️Professional Experience🏥:

  • Resident Physician (1989-1995): Zhongshan Hospital, Fudan University
  • Main Physician and Assistant Researcher (1995-2000): Zhongshan Hospital, Fudan University
  • Associate Researcher (2000-2009): Zhongshan Hospital, Fudan University
  • Doctoral Supervisor (2012-present): Zhongshan Hospital, Fudan University
  • Vice President and Executive Director (2017-2023): Hepatocellular Carcinoma Department, Xiamen Hospital
  • Party Secretary and Executive Director (2023-present): Hepatocellular Carcinoma Department, Xiamen Hospital

🏆Awards:

  1. Standard Academic Contribution Award for Primary Liver Cancer in China (2024)
  2. Top Ten Medical Contribution Experts of “Driving Forward the Industry” (2023)
  3. Advanced Worker in Fujian Health System (2021)
  4. Innovative Entrepreneur of Xiamen Special Economic Zone (2021), celebrating its 40th anniversary
  5. Leading Talent in Medical Disciplines of Xiamen City, Fujian Province (2021)

📚Key Publications:

  1. Early Detection of Cancer, co-edited with Yang Binghui, Fudan University Press, 2003
  2. Liver Cancer in China, co-authored with Yang Binghui, in Screening for Common Malignancies: A Practical Guide, The Humana Press Inc., 2001
  3. Clinical Epidemiology, co-edited, Jiangsu Science & Technology Press, 2018

🔬Research Projects:

  1. Immunosuppressive Microenvironment in Intrahepatic Cholangiocarcinoma, National Natural Science Foundation of Fujian, 2022-2025, Principal Investigator
  2. Precision Diagnosis and Treatment System for Hepatocellular Carcinoma, Key Science and Technology Project of Xiamen, 2019-2023
  3. Innovation Project for High-Risk Hepatocellular Carcinoma Patients, Haicang District Health Bureau, Xiamen, ongoing
  4. Effects of Shuangyouyin on Residual Cancer Cells Post-Chemotherapy, National Natural Science Foundation of China, 2010, Completed

🌐Professional Affiliations:

  • Chairman of the Sixth Committee, Evidence-Based Medicine Professional Committee, China Medical Association
  • Vice Chairman, Fifth Committee, Evidence-Based Medicine Professional Committee, China Medical Association
  • Member, Fifth Council, China Medical Association
  • Member, Eighth Committee, Clinical Epidemiology and Evidence-Based Medicine Branch, Chinese Medical Association
  • Vice Chairman, Shanghai Cancer Association Committee on Cancer Prevention and Screening

Prof. Zhang Boheng is a respected figure in oncology, dedicated to advancing liver cancer diagnostics, treatment, and prevention. His leadership in evidence-based medicine and clinical epidemiology supports his extensive work on hepatocellular carcinoma and contributes significantly to public health.

✨Conclusion:

  • Professor Zhang Boheng stands out as a prominent leader in the field of oncology, particularly in hepatocellular carcinoma research and treatment. His extensive education and training, coupled with decades of clinical and academic experience, have positioned him as an influential figure in advancing cancer care in China. Through his leadership roles and active participation in professional committees, he promotes evidence-based practices and innovative approaches in medicine.

📊🔬NOTABLE PUBLICATION:
  • Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
    • Authors: Zhou, J., Sun, H., Wang, Z., Dong, J., Fan, J.
    • Journal: Liver Cancer
    • Year: 2023

 

  • Development of the Scientific, Transparent and Applicable Rankings (STAR) tool for clinical practice guidelines
    • Authors: Yang, N., Liu, H., Zhao, W., Chen, Y., Wei, J.
    • Journal: Chinese Medical Journal
    • Year: 2023

 

  • Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study
    • Authors: Xu, B., Dong, S.-Y., Bai, X.-L., Rao, S.-X., Sun, H.-C.
    • Journal: Liver Cancer
    • Year: 2023

 

  • A Novel Myeloid Cell Marker Genes Related Signature Can Indicate Immune Infiltration and Predict Prognosis of Hepatocellular Carcinoma: Integrated Analysis of Bulk and Single-Cell RNA Sequencing
    • Authors: Zheng, S.-S., Wu, Y.-F., Zhang, B.-H., Huang, C., Xue, T.-C.
    • Journal: Frontiers in Molecular Biosciences
    • Year: 2023

 

  • Peripheral Lymphocytes in Primary Liver Cancers: Elevated NK and CD8+ T Cells and Dysregulated Selenium Metabolism
    • Authors: Zhou, C., Lu, Z., Sun, B., Wang, Z., Qiu, S.-J.
    • Journal: Biomolecules
    • Year: 2024